MYRBETRIQ: payments to doctors
Payments that named MYRBETRIQ as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $6M
- Providers
- 53,497
- Transactions
- 267,394
- Average per transaction
- $22
The per-transaction average — $22 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 53,497 providers the average total is $112, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Astellas Pharma US Inc | $5,677,419 | 94.4% |
| Astellas Pharma Global Development | $283,266 | 4.7% |
| Astellas Pharma Inc | $38,007 | 0.6% |
| Astellas Pharma Europe BV | $14,393 | 0.2% |